JP2011504462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504462A5 JP2011504462A5 JP2010533046A JP2010533046A JP2011504462A5 JP 2011504462 A5 JP2011504462 A5 JP 2011504462A5 JP 2010533046 A JP2010533046 A JP 2010533046A JP 2010533046 A JP2010533046 A JP 2010533046A JP 2011504462 A5 JP2011504462 A5 JP 2011504462A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- aliphatic
- protein
- arylaliphatic
- dact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98483507P | 2007-11-02 | 2007-11-02 | |
| US5948208P | 2008-06-06 | 2008-06-06 | |
| PCT/SG2008/000420 WO2009058102A1 (en) | 2007-11-02 | 2008-11-03 | Methods and compounds for preventing and treating a tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011504462A JP2011504462A (ja) | 2011-02-10 |
| JP2011504462A5 true JP2011504462A5 (https=) | 2012-01-05 |
Family
ID=40591309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533046A Withdrawn JP2011504462A (ja) | 2007-11-02 | 2008-11-03 | 腫瘍の予防および治療のための方法および化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8969313B2 (https=) |
| EP (1) | EP2217240A4 (https=) |
| JP (1) | JP2011504462A (https=) |
| CN (1) | CN101909630A (https=) |
| SG (1) | SG185942A1 (https=) |
| WO (1) | WO2009058102A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110189097A1 (en) * | 2009-11-09 | 2011-08-04 | Dritan Agalliu | Use of WNT inhibitor to inhibit angiogenesis in the CNS |
| EP2569625A4 (en) * | 2010-05-11 | 2013-12-04 | Ann And Robert H Lurie Children S Hospital Of Chicago | METHOD FOR DETECTING AND PROFILING THE PROGRESS OF THE RISK OF A NEURODEEGENERATIVE DISEASE |
| EP2666020A1 (en) * | 2011-01-18 | 2013-11-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for amplification and detection of prions |
| US9090944B2 (en) | 2011-12-16 | 2015-07-28 | The Chinese University Of Hong Kong | Biomarker DACT1 for gastric cancer |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| CN105567797A (zh) * | 2014-11-11 | 2016-05-11 | 香港中文大学深圳研究院 | 检测DACT2基因启动子区CpG岛甲基化的PCR引物、方法和试剂盒 |
| WO2017019721A2 (en) * | 2015-07-28 | 2017-02-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| GB201516972D0 (en) * | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells |
| FR3042202B1 (fr) * | 2015-10-13 | 2020-02-07 | Institut National De La Recherche Agronomique | Procede de criblage de composes a effet anti-inflammatoire base sur la proteine dact3 et nouvelles strategies therapeutiques |
| US10765471B2 (en) | 2016-04-15 | 2020-09-08 | Bolder Surgical, Llc | Electrosurgical sealer and divider |
| JP7239468B2 (ja) * | 2016-10-06 | 2023-03-14 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける |
| US20180139464A1 (en) * | 2016-11-17 | 2018-05-17 | Mediatek Inc. | Decoding system for tile-based videos |
| CN110408688B (zh) * | 2019-05-22 | 2023-05-02 | 中山大学附属第一医院 | Dact1基因在制备房颤诊断和治疗产品中的应用 |
| CN111802326B (zh) * | 2020-07-09 | 2022-06-17 | 中山大学附属口腔医院 | 一种Kras突变相关口腔黏膜恶变动物模型的构建方法 |
| CN114994323B (zh) * | 2021-02-20 | 2024-12-24 | 中国医学科学院基础医学研究所 | IgG Fc N-糖肽作为确定或辅助肺癌治疗方案选择的标志物的用途 |
| CN114561466B (zh) * | 2022-01-25 | 2023-06-13 | 中山大学附属第一医院 | Fto在诊治骨肉瘤中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57102889A (en) | 1980-12-19 | 1982-06-26 | Toyo Jozo Co Ltd | 2'-(r)-substituted-2'-deoxyneplanocin a derivative |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| JPH02215781A (ja) | 1989-02-14 | 1990-08-28 | Toyo Jozo Co Ltd | ６’―デオキシ―６’―ハロゲノネプラノシンａおよびその製造法 |
| DE69105495T2 (de) | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1994003427A1 (en) | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| JP2002507404A (ja) | 1998-03-27 | 2002-03-12 | ジェネンテク・インコーポレイテッド | Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用 |
| SE517975C2 (sv) | 2000-05-30 | 2002-08-13 | Power Ab C | Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion |
| KR20090089922A (ko) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US20050245559A1 (en) | 2004-01-23 | 2005-11-03 | Koul Hari K | Treatment and prevention of prostate cancer |
| WO2005105136A1 (en) | 2004-04-27 | 2005-11-10 | University Of South Florida | Nanogene therapy for cell proliferation disorders |
| ATE511859T1 (de) | 2004-07-20 | 2011-06-15 | Schering Corp | Apoptoseinduktion in toll-artige rezeptoren exprimierenden tumorzellen |
| JP2009514891A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法 |
| AU2006339445A1 (en) | 2006-03-02 | 2007-09-07 | Agency For Science, Technology And Research | Methods for cancer therapy and stem cell modulation |
| EP2144606A2 (en) | 2007-04-05 | 2010-01-20 | Max-Delbrück-Centrum Für Molekulare Medizin | Remedy for the treatment of cardio-vascular diseases or disorders |
-
2008
- 2008-11-03 CN CN2008801234004A patent/CN101909630A/zh active Pending
- 2008-11-03 JP JP2010533046A patent/JP2011504462A/ja not_active Withdrawn
- 2008-11-03 SG SG2012080990A patent/SG185942A1/en unknown
- 2008-11-03 US US12/740,912 patent/US8969313B2/en not_active Expired - Fee Related
- 2008-11-03 EP EP08844631A patent/EP2217240A4/en not_active Withdrawn
- 2008-11-03 WO PCT/SG2008/000420 patent/WO2009058102A1/en not_active Ceased
-
2015
- 2015-02-20 US US14/628,150 patent/US20160015693A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504462A5 (https=) | ||
| Zhang et al. | Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis | |
| Shen et al. | PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice | |
| Gan et al. | The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter | |
| Jung et al. | Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors | |
| Ma et al. | Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α | |
| Di Domenico et al. | Genetic and epigenetic drivers of neuroendocrine tumours (NET) | |
| Yang et al. | Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma | |
| Eichenmüller et al. | The genomic landscape of hepatoblastoma and their progenies with HCC-like features | |
| Naccarati et al. | Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer | |
| Lipsyc et al. | Impact of somatic mutations on patterns of metastasis in colorectal cancer | |
| Kempinska et al. | Pharmacologic inhibition of the Menin–MLL interaction leads to transcriptional repression of PEG10 and blocks hepatocellular carcinoma | |
| Fan et al. | Genetic and epigenetic regulation of E-cadherin signaling in human hepatocellular carcinoma | |
| EA201290062A1 (ru) | Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений | |
| JP2020536924A5 (https=) | ||
| Stanciu et al. | Serum melatonin is inversely associated with matrix metalloproteinase-9 in oral squamous cell carcinoma | |
| Herrero et al. | The untold stories of the speech gene, the FOXP2 cancer gene | |
| Chou et al. | Combined effect of genetic polymorphisms of AURKA and environmental factors on oral cancer development in Taiwan | |
| Han et al. | NSUN5 facilitates hepatocellular carcinoma progression by increasing SMAD3 expression | |
| Yang et al. | Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway | |
| Ning et al. | Molecular functions and significance of the MTA family in hormone-independent cancer | |
| Huang et al. | KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis | |
| Safarpour et al. | Cholangiocarcinoma and liver transplantation: What we know so far? | |
| Zhou et al. | Homeobox B4 inhibits breast cancer cell migration by directly binding to StAR‑related lipid transfer domain protein 13 | |
| JP2014505877A5 (https=) |